A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : LSCs / leukemia stem cells

[Related PubMed/MEDLINE]
Total Number of Papers: 607
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   LSCs  (>> Co-occurring Abbreviation)
Long Form:   leukemia stem cells
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 A narrative review of central nervous system involvement in acute leukemias. ALL, AML, CNS, CSF, ITT, OS
2021 Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells. AML, ATO, BM
2021 Autonomous TGFβ signaling induces phenotypic variation in human acute myeloid leukemia. AML, ESAM
2021 CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia. A2M, AML, FC, HSCs
2021 Cell signaling pathways as molecular targets to eliminate AML stem cells. AML
2021 Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models. CA, CML, CSCs, DN, PKCdelta, TKI
2021 Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation. CML, DMR, TFR, TKI
2021 Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia. AML, stem
2021 Evaluation of the human type 3 adenoviral dodecahedron as a vector to target acute myeloid leukemia. AML, Dd
10  2021 Exovesicular-Shh confers Imatinib resistance by upregulating Bcl2 expression in chronic myeloid leukemia with variant chromosomes. CML, Shh
11  2021 Functional reconstruction of human AML reveals stem cell origin and vulnerability of treatment-resistant MLL-rearranged leukemia. AML, CMPs, HSCs, MLL
12  2021 Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq. AML
13  2021 Ginsenoside Rg1 induces senescence of leukemic stem cells by upregulating p16INK4a and downregulating hTERT expression. CCK-8, hTERT, PI, RT-PCR
14  2021 Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia. HSPCs, JMML
15  2021 Identification and Targeting of Thomsen-Friedenreich and IL1RAP Antigens on Chronic Myeloid Leukemia Stem Cells Using Bi-Specific Antibodies. BiSAb, CDC, CML, HSC, PBMCs
16  2021 Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics. AML, HSCs
17  2021 Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution. HSPC, MPN, pre-LSC
18  2021 Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis. AML, BafA1, PINK1
19  2021 In vitro and ex vivo anti‑tumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2‑overexpressing leukemia cells. ABCG2, SP
20  2021 Iron Oxide Nanoparticles Combined with Cytosine Arabinoside Show Anti-Leukemia Stem Cell Effects on Acute Myeloid Leukemia by Regulating Reactive Oxygen Species. AML, ROS
21  2021 Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia. BM, CML, CP CML, DMR, FCM, PB, TFR
22  2021 LIGHT/LTβR signaling regulates self-renewal and differentiation of hematopoietic and leukemia stem cells. CML, HSC, LTbetaR
23  2021 Loss of FGFR3 Delays Acute Myeloid Leukemogenesis by Programming Weakly Pathogenic CD117-Positive Leukemia Stem-Like Cells. AML, CML, FGFR3
24  2021 Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells. CML, HSCs
25  2021 microRNA-1246-containing extracellular vesicles from acute myeloid leukemia cells promote the survival of leukemia stem cells via the LRIG1-meditated STAT3 pathway. AML, EVs, miR-1246
26  2021 One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia. AML, Tim-3
27  2021 Recent advances in understanding chronic myeloid leukemia: where do we stand? TFR
28  2021 Recent progress on targeting leukemia stem cells. HSCs
29  2021 Taming Cell-to-Cell Heterogeneity in Acute Myeloid Leukaemia With Machine Learning. AML, ML
30  2021 Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy. ---
31  2021 Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6. CML, TKIs
32  2021 Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. 8-Cl-Ado, AML, FAO, GSEA, OCR, OXPHOS, VEN
33  2020 A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients. IPSS-R, LFS, MDS, OS
34  2020 A general view of CD33+ leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy. AML, mAb
35  2020 A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells. CAR, CML
36  2020 A small molecule compound IX inhibits telomere and attenuates oncogenesis of drug-resistant leukemia cells. HSCs, PDX
37  2020 A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. AML, HSCs, NK, scFv, sdAb
38  2020 Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells. AML, iPSCs
39  2020 Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. ---
40  2020 AICAR and Decitabine Enhance the Sensitivity of K562 Cells to Imatinib by Promoting Mitochondrial Activity. AICAR, CML, TKIs
41  2020 AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growth. CML, ROS, UPR
42  2020 Analysis and Isolation of Mouse Leukemic Stem Cells. HSCs
43  2020 Arrayed Molecular Barcoding of Leukemic Stem Cells. ---
44  2020 Budgeting at the Ca2+ store: a PIP(2)eline to starve LSCs? AML, ER, ORPs, PM
45  2020 CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. AML, CRL4CRBN
46  2020 CD123 as a Therapeutic Target Against Malignant Stem Cells. HSCs
47  2020 CD45dimCD34+CD38-CD133+ cells have the potential as leukemic stem cells in acute myeloid leukemia. AML, HC
48  2020 CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. CML
49  2020 Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models. AML, IAP, MDR1i, SM
50  2020 Cluster of Differentiation 96 in Children with Acute Leukemia: A Single Center Cohort Study. AL, ALL, AML, CD96
51  2020 CXCR4 Antagonists as Stem Cell Mobilizers and Therapy Sensitizers for Acute Myeloid Leukemia and Glioblastoma? AML, CXCR4, GSCs, HSC, SDF-1alpha
52  2020 Cytotoxic and Apoptotic Effects of Luffa Cylindrica Leaves Extract against Acute Lymphoblastic Leukemic Stem Cells. ALL, L.C
53  2020 Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature. AML, TKIs
54  2020 Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML. AML, BM, CML
55  2020 Detection of residual disease in chronic myeloid leukemia utilizing genomic next generation sequencing reveals persistence of differentiated Ph+ B cells but not bone marrow stem/progenitors. CML, MRD, SPCs, TKIs
56  2020 Disrupting Mitochondrial Copper Distribution Inhibits Leukemic Stem Cell Self-Renewal. AML, MIA, SAHH, SAM
57  2020 Disruption of CTCF Boundary at HOXA Locus Promote BET Inhibitors' Therapeutic Sensitivity in Acute Myeloid Leukemia. BETi
58  2020 Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis. HSCs
59  2020 E35 ablates acute leukemia stem and progenitor cells in vitro and in vivo. AL
60  2020 Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells. CML, LSK, TKI
61  2020 Evaluation of Silencing Effect of miR-133a-5p Mimic on TIM-3 Expression in AML (HL-60) Cell Line. AML, miRNAs, Tim-3
62  2020 Evi1 Counteracts Anti-Leukemic and Stem Cell Inhibitory Effects of All-Trans Retinoic Acid on Flt3-ITD/Npm1c-Driven Acute Myeloid Leukemia Cells. AML, ATRA
63  2020 Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes. AML, HSCs
64  2020 Extinguishing the Embers: Targeting AML Metabolism. AML
65  2020 FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML. MA9
66  2020 Ginsenoside Rg1 Inhibits Cell Proliferation and Induces Markers of Cell Senescence in CD34+CD38- Leukemia Stem Cells Derived from KG1alpha Acute Myeloid Leukemia Cells by Activating the Sirtuin 1 (SIRT1)/Tuberous Sclerosis Complex 2 (TSC2) Signaling Pathway. AML, CCK-8, qRT-PCR, SA ss-gal, SIRT1, TSC2
67  2020 High Expression of the SH3TC2-DT/SH3TC2 Gene Pair Associated With FLT3 Mutation and Poor Survival in Acute Myeloid Leukemia: An Integrated TCGA Analysis. AML, DEGs, DElncRNAs, DEmRNAs, FLT3, SH3TC2-DT, WGCNA
68  2020 Hypoxic exposure activates the B cell-specific Moloney murine leukaemia virus integration site 1/PI3K/Akt axis and promotes EMT in leukaemia stem cells. AML, BMI1, EMT, HIF
69  2020 Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia. AhR, AML, FICZ, FLT3
70  2020 Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors. CML, ILK, TKIs
71  2020 Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia. CML, TKI
72  2020 Leukemia Stem Cells: Concept and Implications. CSCs
73  2020 Leukemic Stem Cell Culture in Cytokine-Free Medium. AML
74  2020 Location First: Targeting Acute Myeloid Leukemia Within Its Niche. AML, BM
75  2020 Low-Dose Triptolide Enhanced Activity of Idarubicin Against Acute Myeloid Leukemia Stem-like Cells Via Inhibiting DNA Damage Repair Response. AML, IDA, TPL
76  2020 Mitochondria: A Galaxy in the Hematopoietic and Leukemic Stem Cell Universe. Bcl-2, HSCs, OXPHOS, ROS
77  2020 Modeling Leukemia Stem Cells with Patient-Derived Induced Pluripotent Stem Cells. AML, iPSCs
78  2020 Modulators of histone demethylase JMJD1C selectively target leukemic stem cells. JDM-7
79  2020 Myc-Miz1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpα and Cebpδ. AMLs, HSPCs, Miz1, MycV394D
80  2020 Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. AML, NAMPT, R/R
81  2020 Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells. CML, HDAC, TKIs
82  2020 OMIP 072: A 15-color panel for immunophenotypic identification, quantification, and characterization of leukemic stem cells in children with acute myeloid leukemia. AML, BM, HSCs, MNCs
83  2020 Oxidative resistance of leukemic stem cells and oxidative damage to hematopoietic stem cells under pro-oxidative therapy. BM, HSCs, ROS
84  2020 PERK/NRF2 and autophagy form a resistance mechanism against G9a inhibition in leukemia stem cells. AML, ROS
85  2020 Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells. HSPCs
86  2020 Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions. AML
87  2020 Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. AML, HMAs
88  2020 Targeting LSCs: Peeling Back the Curtain on the Metabolic Complexities of AML. ---
89  2020 Targeting mitochondrial respiration for the treatment of acute myeloid leukemia. AML, ETC, HSCs, OXPHOS
90  2020 Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. AML, Hh, RTK
91  2020 Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells. BM, CML, PAI-1, TKI
92  2020 The Dual Role of ROS in Hematological Malignancies: Stem Cell Protection and Cancer Cell Metastasis. BM, HSCs, ROS
93  2020 The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. AML, CML
94  2020 The N6-methyladenosine RNA modification in acute myeloid leukemia. AML, m6A
95  2020 The Role Played by Wnt/beta-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia. ALL
96  2020 Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia. CML, ITIM, TKI
97  2020 Tracing Leukemia Stem Cells and Their Influence on Clinical Course of Adult Acute Myeloid Leukemia. AML, CI, DFS, HR, MRD, OS
98  2020 Wnt Signaling in Leukemia and Its Bone Marrow Microenvironment. HSC, MSC
99  2020 WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target. AML, Bcl-2, LICs, WT1
100  2020 Zeb1 modulates hematopoietic stem cell fates required for suppressing acute myeloid leukemia. AML, EMT, EpCAM, HSCs, KO